Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-369-5p lentiviral silencing is an experimental gene therapy approach designed to inhibit the invasion of glioblastoma multiforme (GBM) cells. miR-369-5p was identified as a microRNA significantly upregulated in invasive GBM cells compared to the tumor core. By utilizing a lentiviral vector to deliver silencing machinery (such as shRNA) against miR-369-5p, researchers observed a suppression of GBM cell migration in vitro and a significant inhibition of invasive growth in vivo using patient-derived orthotopic xenograft (PDOX) models. The silencing of miR-369-5p appears to modulate the expression of target genes like RDX and MANEA, which are involved in tumor cell motility and invasion.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-369-5p lentiviral silencing.